P1125: DURABLES RESPONSES ACHIEVED WITH ANTI-CD19 ALLOGENEIC CAR T ALLO-501/501A IN PHASE 1 TRIALS OF AUTOLOGOUS CAR T-NAÏVE PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (R/R LBCL)

• Javier Munoz,
• Frederick Locke,
• Lazaros Lekakis,
• Herbert Eradat,
• Michael Tees,
• Sven de Vos,
• Rajneesh Nath,
• Don Stevens,
• Shahbaz Malik,
• Leslie Popplewell,
• Mehdi Hamadani,
• Olalekan Oluwole,
• Miguel-Angel Perales,
• David Miklos,
• Paul Fisher,
• Lovely Goyal,
• Lynn Navale,
• Gregory Kaufman,
• Kazuharu Kai,
• Arun Balakumaran,
• Sattva Neelapu

Affiliations

Javier Munoz

1 Mayo Clinic Comprehensive Cancer Center, Dept of Hematology, Phoenix, United States

Frederick Locke

2 Moffitt Cancer Center, Magnolia Campus, Tampa, United States

Lazaros Lekakis

3 University of Miami, Coral Gables, United States

Herbert Eradat

4 Ronald Reagan UCLA Medical Center, Los Angeles, United States

Michael Tees

5 Colorado Blood Cancer Institute, Denver, United States

Sven de Vos

6 UCLA, Los Angeles, United States

Rajneesh Nath

7 Banner Health Center, Gilbert, United States

Don Stevens

8 Norton Cancer Institute, Louisville, United States

Shahbaz Malik

9 St. David’s South Austin Medical Center, Sarah Cannon Transplant & Cellular Therapy Program, Austin, United States

Leslie Popplewell

10 City of Hope Medical Center, Duarte, United States

Mehdi Hamadani

11 Medical College of Wisconsin, Milwaukee, United States

Olalekan Oluwole

12 Vanderbilt Medical Center, Nashville, United States

Miguel-Angel Perales

13 Memorial Sloan Kettering Cancer Center New York, New York, United States

David Miklos

14 Stanford University, Stanford, United States

Paul Fisher

15 Allogene Therapeutics, South San Francisco, United States

Lovely Goyal

15 Allogene Therapeutics, South San Francisco, United States

Lynn Navale

15 Allogene Therapeutics, South San Francisco, United States

Gregory Kaufman

15 Allogene Therapeutics, South San Francisco, United States

Kazuharu Kai

15 Allogene Therapeutics, South San Francisco, United States

Arun Balakumaran

15 Allogene Therapeutics, South San Francisco, United States

Sattva Neelapu

16 The University Of Texas MD Anderson Cancer Center, Houston, United States